Abstract:<p>The complement system was discovered at the end of the 19th century as a heat-labile plasma component that "complemented" the antibodies in killing microbes, hence the name "complement." Complement is also part of the innate immune system, protecting the host by recognition of pathogen-associated molecular patterns. However, complement is multifunctional far beyond infectious defense. It contributes to organ development, such as sculpting neuron synapses, promoting tissue regeneration and repair, and rapidly engaging and synergizing with a number of processes, including hemostasis leading to thromboinflammation. Complement is a double-edged sword. Although it usually protects the host, it may cause tissue damage when dysregulated or overactivated, such as in the systemic inflammatory reaction seen in trauma and sepsis and severe coronavirus disease 2019 (COVID-19). Damage-associated molecular patterns generated during ischemia-reperfusion injuries (myocardial infarction, stroke, and transplant dysfunction) and in chronic neurologic and rheumatic disease activate complement, thereby increasing damaging inflammation. Despite the long list of diseases with potential for ameliorating complement modulation, only a few rare diseases are approved for clinical treatment targeting complement. Those currently being efficiently treated include paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, myasthenia gravis, and neuromyelitis optica spectrum disorders. Rare diseases, unfortunately, preclude robust clinical trials. The increasing evidence for complement as a pathogenetic driver in many more common diseases suggests an opportunity for future complement therapy, which, however, requires robust clinical trials; one ongoing example is COVID-19 disease. The current review aims to discuss complement in disease pathogenesis and discuss future pharmacological strategies to treat these diseases with complement-targeted therapies.</p>Significance Statement<p>The complement system is the host's defense friend by protecting it from invading pathogens, promoting tissue repair, and maintaining homeostasis. Complement is a double-edged sword, since when dysregulated or overactivated it becomes the host's enemy, leading to tissue damage, organ failure, and, in worst case, death. A number of acute and chronic diseases are candidates for pharmacological treatment to avoid complement-dependent damage, ranging from the well established treatment for rare diseases to possible future treatment of large patient groups like the pandemic coronavirus disease 2019.</p>

Complement as a target in COVID-19?

Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics

Implications of Complement Imbalance in COVID-19: A Molecular Mechanistic Discussion on the Importance of Complement Balance

Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy

The state of complement in COVID-19

Complement system activation: bridging physiology, pathophysiology, and therapy

Emerging role of complement in COVID-19 and other respiratory virus diseases

Clinical promise of next-generation complement therapeutics

Complement in disease: a defence system turning offensive

Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review

The complement system: A key player in the host response to infections

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients

Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature

Complement in neurological disorders and emerging complement-targeted therapeutics

Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection

Role of the complement system in Long COVID

Prognostic Significance of the Coagulation and Complement Systems in Critical COVID-19 Infection

Terminal complement inhibition dampens the inflammation during COVID‐19

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations

Enhanced complement activation and MAC formation accelerates severe COVID-19